Market closed

BeyondSpring/$BYSI

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About BeyondSpring

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.

Ticker

$BYSI

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Florham Park, United States

Employees

Website

beyondspringpharma.com

BeyondSpring Metrics

BasicAdvanced

$66M

-

-$0.40

0.26 -

Price and volume

Market cap

$66M

Beta

0.26

52-week high

$4.00

52-week low

$0.82

Average daily volume

27K

Financial strength

Current ratio

1.822

Quick ratio

1.754

Long term debt to equity

-11.532

Total debt to equity

-14.029

Management effectiveness

Return on assets (TTM)

-39.64%

Return on equity (TTM)

78.43%

Valuation

Price to revenue (TTM)

34.341

Price to book

-2.2

Price to tangible book (TTM)

-2.2

Growth

Revenue change (TTM)

21.03%

Earnings per share change (TTM)

-43.40%

3-year revenue growth (CAGR)

29.89%

3-year earnings per share growth (CAGR)

-40.82%

What the Analysts think about BeyondSpring

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for BeyondSpring stock.

BeyondSpring Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

BeyondSpring Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

BeyondSpring News

AllArticlesVideos

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BYSI

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BeyondSpring stock?

BeyondSpring (BYSI) has a market cap of $66M as of January 15, 2025.

What is the P/E ratio for BeyondSpring stock?

The price to earnings (P/E) ratio for BeyondSpring (BYSI) stock is 0 as of January 15, 2025.

Does BeyondSpring stock pay dividends?

No, BeyondSpring (BYSI) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next BeyondSpring dividend payment date?

BeyondSpring (BYSI) stock does not pay dividends to its shareholders.

What is the beta indicator for BeyondSpring?

BeyondSpring (BYSI) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.